Medroxyprogesterone Acetate Injectable Suspension Injection, Suspension
FDA Label NDC 24201-150

48 label sections · Submitted to the FDA by Hikma Pharmaceuticals Usa Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Hikma Pharmaceuticals Usa Inc. for the product Medroxyprogesterone Acetate Injectable Suspension (NDC 24201-150). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: loss of bone mineral density, 1 indications and usage, 2.1 prevention of pregnancy, 2.2 switching from other methods of contraception, 3 dosage forms and strengths, 4 contraindications, 5.1 loss of bone mineral density, 5.2 thromboembolic disorders, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.